What's new

[PIO] Inclusion of new drugs for the treatment of type 2 diabetes mellitus in the GESY

29141.jpg





The Health Insurance Organisation (HIO) wishes to inform beneficiaries that from Friday 15/07/2022 the following drugs of the SGLT-2 inhibitor class for patients with type 2 diabetes mellitus will be available from the GHS:

  1. FORXIGA TABLET 10MG
  2. INVOKANA TABLET 100MG and INVOKANA TABLET 300MG
  3. JARDIANCE TABLET 10MG and JARDIANCE TABLET 25MG
  4. STEGLATRO TABLET 15MG and STEGLATRO TABLET 5MG
  5. SYNJARDY TABLET 12.5MG/1000MG, SYNJARDY TABLET 12.5MG/850MG, SYNJARDY TABLET 5MG/1000MG and SYNJARDY TABLET 5MG/850MG
  6. VOKANAMET TABLET 150MG/1000MG, VOKANAMET TABLET 150MG/850MG, VOKANAMET TABLET 50MG/1000MG, VOKANAMET TABLET 50MG/850MG
  7. XIGDUO TABLET 5MG/1000MG, XIGDUO TABLET 5MG/850MG

The prescription via the GHS Information System of the above pharmaceutical products will be possible provided that:

  1. made by Adult Personal Physicians, Geriatricians and Endocrinologists
  2. beneficiaries meet the protocol criteria.

Beneficiaries are requested to contact their treating physician to find out whether they meet these criteria.

(NΓ/ΣX)
Contents of this article including associated images are owned by PIO
Views & opinions expressed are those of the author and/or PIO

Source

[/P][/P]Source[/URL][/P]
 
Back
Top